SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck
MRK 99.21+1.0%Dec 17 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David C. Burns who wrote (1547)11/9/2007 10:49:27 AM
From: Carey Thompson  Read Replies (1) of 1580
 
This $4.5 billion settlement of the VIOXX cases is good for Merck.

I still think Merck did the right thing pulling VIOXX off the market back in 2004 when Merck discovered VIOXX could linked to heart disease and strokes. Remember VIOXX did not cause heart disease and strokes but it did not help either. So, Merck followed the Hipprocratic oath to "do no harm".

Financially, the $4.5 bill charge to 4q2007 earnings may result in yearly revenues of $26 bill and yearly net income of $1.5 bill. Before I estimated the same revenues but net income of $6.3 bill. For perspective, recent actual amounts are:
            revs           net income    billions of $$$s

2006             22.6          4.4
2005             22.0          4.6
2004             22.9          5.8
2003             22.5          6.8


So operationally, Merck is making more money and its price should follow its improved earnings. I hope the VIOXX charge does not overshadow Merck's improved profitability.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News